PDA

View Full Version : Americans for Safe Access: Marijuana Remains Schedule I



painretreat
01-24-2013, 01:18 AM
(http://www.csindy.com/IndyBlog/archives/2013/01/22/marijuana-stays-schedule-i&show=comments):mad: (http://www.csindy.com/IndyBlog/archives/2013/01/22/marijuana-stays-schedule-i&show=comments)
Marijuana stays Schedule I | (http://www.csindy.com/IndyBlog/archives/2013/01/22/marijuana-stays-schedule-i&show=comments)
Appellate decision puts the ball in your court (http://safeaccessnow.org/blog/blog/2013/01/22/appellate-decision-puts-the-ball-in-your-court/)

January 22nd, 2013
Posted by Don Duncan http://safeaccessnow.org/blog/wp-content/uploads/2012/05/USCapitol-150x150.jpg (http://safeaccessnow.org/blog/blog/2012/05/08/why-we-fight-for-medical-cannabis-and-how-congress-can-help-us-win/uscapitol/)The US appellate court in Washington, DC, denied our appeal to reschedule cannabis under federal law (http://americansforsafeaccess.org/downloads/DC_Circuit_Ruling_ASA_v_DEA.pdf)today, agreeing with the Drug Enforcement Administration??s (DEA) position that ??adequate and well-controlled studies? on the medical efficacy of medical cannabis do not exist. Americans for Safe Access (ASA) strongly disagrees with the court??s opinion. Our briefs (http://americansforsafeaccess.org/downloads/CRC_Appeal.pdf)referenced two hundred peer-reviewed scientific studies proving the medical value of cannabis.
The Obama Administration keeps changing the definition of medical efficacy. Politics have trumped medical science on this issue. ASA can point to a research approval process for medical cannabis, controlled by the National Institute on Drug Abuse (NIDA), which is unique, overly rigorous, and hinders meaningful therapeutic research. ASA argued in its appeal brief that the DEA has no ??license to apply different criteria to marijuana than to other drugs, ignore critical scientific data, misrepresent social science research, or rely upon unsubstantiated assumptions, as the DEA has done in this case.?
The decision in Americans for Safe Access v. Drug Enforcement Administration (http://americansforsafeaccess.org/downloads/CRC_Appeal.pdf)is disappointing, but not the end of the road. ASA will seek an en banc review, asking all nine judges to review the two-to-one decision by a three-judge panel that heard oral arguments in October of last year. If the full nine-member panel does not reverse the decision, we will ask the US Supreme Court to hear the case. In the meantime, the ball is in your court. We must now turn to Congress to do what the courts have not. ASA is calling on patients and advocates to join us in Washington, DC, February 22-25, for our national conference and historic citizen lobby day (http://safeaccessnow.org/blog/conference2013/).
The conference, called ??Bridging the Gap between Public and Policy,? is a chance to network with other activists from around the country, attend panels and workshops to improve your skills and increase your knowledge, and to engage in direct citizen-lobbying efforts in the halls of Congress on Monday, February 25. Our goals are to bring medical cannabis into the mainstream political conversation in the nation??s capitol and to send an army of motivated and empowered activists back home to work at the local and state level. The courts may not be ready to acknowledge that cannabis is medicine ?? but we are going to be sure Congress and the Obama Administration get the message. Do not miss your chance to be a part of it. Register for the conference today! (http://safeaccessnow.org/blog/conference2013/)
ASA??s national conference is sponsored by the International Association of Cannabinoid Medicines, Patients Out of Time, the United Food and Commercial Workers Union, Veterans for Medical Marijuana Access, the American Herbal Products Association, and Students for Sensible Drug Policy. Scholarships are made possible by a generous matching funds contribution from Dr. Bronner??s Magic Soap.
See you in Washington, DC!

Marijuana stays Schedule I | (http://www.csindy.com/IndyBlog/archives/2013/01/22/marijuana-stays-schedule-i&show=comments)


Marijuana stays Schedule I

Posted by Bryce Crawford (http://www.csindy.com/coloradosprings/ArticleArchives?author=1425904) on Tue, Jan 22, 2013 at 4:23 PM

http://www.csindy.com/binary/831d/1358893867-shutterstock_121570756.jpg

Shutterstock (http://www.csindy.com/coloradosprings/ImageArchives?by=2553835)


Finally, we may be reaching the end of a story we've been following for almost 18 months (http://www.csindy.com/IndyBlog/archives/2011/05/23/advocates-sue-over-delayed-marijuana-reclassification-petition): the attempt by Americans for Safe Access (http://safeaccessnow.org/), and related parties, to see marijuana rescheduled from its current status as a Schedule I substance, which has taken the group from a 2002 petition to a 2011 denial, to a subsequent lawsuit.
Today, the U.S. Court of Appeals in Washington D.C. rejected ASA's argument that the Drug Enforcement Administration's "final order denying their request to initiate proceedings to reschedule marijuana was arbitrary and capricious," reads the judgment (http://www.cadc.uscourts.gov/internet/opinions.nsf/12CBD2B55C34FBF585257AFB00554299/$file/11-1265-1416392.pdf) written by Judge Harry T. Edwards.
So, basically, ASA's request to reschedule the drug to Schedule III, IV or V was rejected. Then its lawsuit saying the rejection was illogical ?? and not taking into account research that's already out there regarding cannabis' medical benefits ?? was rejected by the court.
There was a small highlight early in the case, when ASA maneuvered around and narrowly kept its standing (http://en.wikipedia.org/wiki/Standing_%28law%29). Unfortunately, the outcome of the whole thing hinged on portraying the bureaucracy of the DEA in a certain negative light, which was always a longshot.
"Under the Administrative Procedure Act, a court may set aside an agency??s final decision only if it is 'arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law,'" it reads. "We will not disturb the decision of an agency that has ??examine[d] the relevant data and articulate[d] a satisfactory explanation for its action including a rational connection between the facts found and the choice made.'"
Here's the DEA's reasoning regarding one of its five conditions of rescheduling, that the substance have proven medical use.
"To establish accepted medical use, the effectiveness of a drug must be established in well-controlled, well designed, well-conducted, and well-documented scientific studies, including studies performed in a large number of patients," it wrote in its initial rejection of ASA's request. "To date, such studies have not been performed. The small clinical trial studies with limited patients and short duration are not sufficient to establish medical utility."
The court said that the DEA would only consider studies that were as rigorous as what the Food and Drug Administration would put new drug applicants through, and that just any "peer-reviewed" study would not be sufficient.
"To deny that sufficient evidence is lacking on the medical efficacy of marijuana is to ignore a mountain of well-documented studies that conclude otherwise," says Joe Elford, chief counsel with ASA, in a statement. "The Court has unfortunately agreed with the Obama Administration's unreasonably raised bar on what qualifies as an 'adequate and well-controlled' study, thereby continuing their game of 'Gotcha.'"
Regardless of where you stand on marijuana's medical benefits, it's not hard to see the DEA took its sweet time deciding the issue. ASA and others (called the Coalition for Rescheduling Cannabis) first filed their petition in 2002. Nine years later, in 2011, the DEA rejected it, after being sued for the first time, which was five years after it had received the U.S. Department of Health and Human Services' opinion in 2006 that there was not enough proof of medical efficacy.
"The Obama Administration's legal efforts will keep marijuana out of reach for millions of qualified patients who would benefit from its use," says Elford, noting the group would appeal the ruling to the U.S. Supreme Court if necessary. "It's time for President Obama to change his harmful policy with regard to medical marijuana and treat this as a public health issue, something entirely within the capability and authority of the executive office."
Americans for Safe Access v. DEA (http://www.scribd.com/doc/121646900/Americans-for-Safe-Access-v-DEA) by Mike Riggs: the text of the case is after this, in the link.



(http://www.scribd.com/mike_riggs_13)

boaz
01-26-2013, 03:31 AM
The one dissenting argument wasn't even ruling for ASA, et al. but ruling that they didn't even qualify to be there under Article III. The Court opinion was that they qualified to be there under Article III but still failed to prove that the DEA was arbitrary, capricious and such.

Article III means the plaintiff must prove harm and causation. The court ruled that one party did, the medical Veteran from Oregon. The dissenting ruling argued that he did not meet this definition because the VA does not deny medical benefits to medical cannabis users in the free states.

I'm not an attorney this is just what I learned from reading this. The idea that anyone could find no evidence of medical use is beyond me. Also, the fact that the DOJ/DEA/DHHS/DeptofRedundancyDept/etc. and all these other alphabet of Article III executive branch agencies can write legislation under the CSA and this not be unconstitutional is beyond me. Not to mention the fact that the DEA pyramid depends on the very laws it is writing for its annual funding from Congress. How can this be legal?

Best of luck with the appeal. If you guys need a medical Veteran from a non medical cannabis state then I have a friend that is perfect. He was told he would lose his VA benefits if he tested positive to cannabis but needs both to help deal with the pain from his injuries he sustained while in the service. I believe this satisfy all the elements of the Article III qualification needed to argue in federal appeals court.



================================================
Opinion for the Court filed by Senior Circuit Judge
EDWARDS.

Under the Administrative Procedure Act, a court may set
aside an agency??s final decision only if it is ??arbitrary,
capricious, an abuse of discretion, or otherwise not in
accordance with law.?

Dissenting opinion filed by Circuit Judge HENDERSON.

KAREN LECRAFT HENDERSON, Circuit Judge, dissenting
----------------------------------------------------
To press their claim, the petitioners must establish that at
least one of them has standing. ..
Article III standing has three elements: ??(1) injury-in-fact, (2)
causation, and (3) redressability.?

boaz
01-26-2013, 03:51 AM
also, this just occurred to me, :stoned: Altho it is wonderful that, if in fact true, the VA allows med users to use in free states doesn't this very fact raise an issue. Can a federal agency have two different national policies of this importance that depends solely on which state you live in? this seems to me to fit the definition of “arbitrary,capricious, an abuse of discretion, or otherwise not in accordance with law.” but I'm no attorney.

but perhaps in accordance with the US Constitution. i don't know, time to get fast food. :jointsmile:

boaz
01-28-2013, 01:22 PM
correction: I meant to say Article II Executive Branch agencies. Article III, of course, is the Judicial Branch.

boaz
02-01-2013, 03:26 PM
How many medical pot studies will it take? | Which Way L.A.? (http://blogs.kcrw.com/whichwayla/2013/01/how-many-medical-pot-studies-will-it-take)

How many medical pot studies will it take?

24 January 2013 by: Evan George (http://blogs.kcrw.com/whichwayla/author/evangeorge)



When a federal appeals court this week (http://www.sltrib.com/sltrib/world/55678205-68/marijuana-court-medical-dea.html.csp) snuffed out the possibility of re-classifying marijuana, it did so with a simple argument: pot has no ??currently accepted medical use.? What would it take to change its tune? ??Adequate and well-controlled studies proving efficacy,? according to the Drug Enforcement Agency.

So, how is it possible that the problem is a simple lack of studies? Researchers have been studying marijuana (http://www.cmcr.ucsd.edu/index.php?option=com_content&view=category&id=41&Itemid=135) for decades. Actually anyone who??s ever read the back pages of a city rag can testify that medical marijuana studies are rampant. And not all of them are clinical trials that sell themselves as ??Want to Smoke Weed and Get Paid?? There are about 100 on-going trials (http://www.slate.com/articles/health_and_science/explainer/2012/11/how_do_you_get_to_participate_in_a_marijuana_resea rch_study.html) listed by the National Institutes of Health. Consider a fascinating sample list of health conditions for which medical pot has been tried as treatment (emphasis is mine):

Nausea and Vomiting, Appetite Loss, Spasticity, Headache/Migraine, Amyotrophic Lateral Sclerosis, Bladder Dysfunction, Gastro-Oesophageal Reflux, Irritable Bowel Syndrome, Diarrhoea, Crohn??s Disease, Ulcerative Colitis, Obstetrics and Gynecology, Tremor, Dystonia, Hiccups, Tourette??s Syndrome, Tics, Hyperkinetic Movement Disorder, Attention-Deficit/Hyperactivity Disorder, Obsessive Compulsive Disorder, Trichotillomania, Parkinson??s Disease, Huntington??s Disease, Traumatic Brain Injury, Tinnitus, Pruritus, Night Sweats, Epilepsy, Isaacs?? Syndrome, Intraocular Pressure, Night Vision, Asthma, Bronchodilation, Blood Pressure/Hypertension, Cancer, Alzheimer??s Disease, Neuroprotection, Schizophrenic Psychosis, Bipolar Disorder, Depression, Anxiety, Posttraumatic Stress Disorder, Alcohol Dependency, Opioid Dependency, Cocaine/Crack Dependency, Cannabis Dependency, Sleep


In fact, Americans for Safe Access cited more than 200 published studies demonstrating marijuana??s efficacy for various medical uses, including a 1999 study by the respected Institute of Medicine, a government adviser on health issues. So what gives?

Basically the feds aren??t stoked on the quality of the research. The peer-reviewed studies are considered ??phase I? testing under the FDA??s criteria and don??t meet the ??phase II or III? definition based on how long the clinical trial extend and the limited number of participants involved. That??s according to Alex Kreit, associate professor at the Thomas Jefferson School of Law in San Diego, who specializes in controlled substance law. Kreit says he was a little surprised the court accepted the DEA??s line of argument without deeper consideration of the quality and quantity of study that??s been performed over the years, but he expects it will be the subject of appeals. More on tonight??s show with Kreit about the Los Angeles medical marijuana ballot initiatives, here (http://www.kcrw.com/news/programs/ww/).

You can hear the Which Way, LA? on this topic, below: